Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only.All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

Klow_80MG

KLOW

KLOW Blend is a multi-component research peptide formulation combining four extensively studied bioactive peptides: BPC-157, TB-500 (Thymosin Beta-4 fragment), KPV, and GHK-Cu. This blend is designed for laboratory research investigating cellular signaling, tissue modeling, peptide synergy, and regenerative pathway interactions in controlled experimental systems.*

Each peptide included in KLOW Blend has been individually studied in scientific literature for its role in cell migration, extracellular matrix signaling, inflammatory pathway modulation, angiogenic signaling, and peptide–receptor communication. When combined, these peptides provide researchers with a single, unified formulation for exploring multi-pathway peptide interactions in vitro.*

  • Product Name: KLOW Blend
  • Total Peptide Content: 80 mg per vial
  • Composition:
    • 10mg BPC-157 (Pentadecapeptide)
    • 10mg TB-500 (Thymosin Beta-4 fragment)
    • 10mg KPV (Tripeptide fragment of α-MSH)
    • 50mg GHK-Cu (Copper tripeptide complex)
  • Form: Lyophilized powder
  • Purity: ≥99% combined peptide purity (HPLC verified)
  • Analytical Verification: HPLC and Mass Spectrometry (MS)
  • Manufacturing: Solid-phase peptide synthesis with controlled blending
  • Designation: For Research Use Only (RUO)

$175.00

$166.25 each
$157.50 each

Products will arrive in a lyophilized (powder) form for maximum stability.

Free domestic shipping on orders over $300

KLOW

Scientific & Research Context

KLOW Blend is intended for advanced peptide research where multi-factor signaling environments are required. In published research, the individual components of this blend have been examined for their roles in:*

  • Cellular migration and cytoskeletal organization*

  • Angiogenic and vascular signaling pathways*

  • Extracellular matrix remodeling and fibroblast activity*

  • Inflammatory response modulation and cytokine signaling*

  • Peptide-driven wound-healing and tissue-repair models*

Researchers may utilize KLOW Blend to explore synergistic or complementary peptide effects, compare single-peptide versus combination responses, and model complex biological systems where multiple peptide signals are present simultaneously.*

Quality & Analytical Assurance

Each batch of KLOW Blend undergoes stringent analytical verification to confirm identity, purity, and composition accuracy. High-performance liquid chromatography (HPLC) and mass spectrometry (MS) are used to ensure peptide integrity and batch-to-batch consistency. All blending is performed under controlled conditions to preserve molecular stability and reproducibility.

Storage & Handling

KLOW Blend is supplied in lyophilized form to maximize stability during storage and transport. Store unopened vials in a cool, dry environment protected from light. Reconstitution and handling should follow established laboratory peptide protocols and aseptic techniques to maintain molecular integrity and experimental reliability.

For further information on proper storage techniques, click the button…

Storage Instructions

Referenced Scientific Literature
Provided for informational and educational purposes only

  • Chang C-H et al., “The promoting effect of pentadecapeptide BPC-157 on tendon healing involves tendon outgrowth, cell survival, and cell migration,” Journal of Applied Physiology, 2010.
  • Šikiric P et al., “Novel cytoprotective mediator, stable gastric pentadecapeptide BPC-157: vascular recruitment and gastrointestinal tract healing,” Current Pharmaceutical Design, 2018.
  • Seiwerth S et al., “BPC-157 and standard angiogenic growth factors: lessons from tendon, ligament, muscle and bone healing,” Current Pharmaceutical Design, 2018.
  • Hsieh M-J et al., “Therapeutic potential of pro-angiogenic BPC-157 is associated with VEGFR2 activation,” Journal of Molecular Medicine, 2017.
  • Philp D et al., “Thymosin β4 promotes angiogenesis, wound healing, and hair follicle development,” Mechanisms of Ageing and Development, 2004.
  • Chopp M and Zhang Z. G., “Thymosin β4 as a restorative/regenerative therapy for neurological injury and neurodegenerative diseases,” Expert Opinion on Biological Therapy, 2015.
  • Dubé K. N. and Smart N., “Thymosin β4 and the vasculature: multiple roles in development, repair and protection against disease,” Expert Opinion on Biological Therapy, 2018.
  • Cheng P et al., “Beneficial effects of thymosin β4 on spinal cord injury in the rat,” Neuropharmacology, 2014.
  • Brzoska T et al., “α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects,” Endocrine Reviews, 2008.
  • Catania A et al., “The neuropeptide α-MSH in inflammation and immunity,” Peptides, 2004.
  • Pickart L and Margolina A., “Regenerative and protective actions of the GHK-Cu peptide in the light of new gene data,” International Journal of Molecular Sciences, 2018.
  • Maquart F. X. et al., “Stimulation of collagen synthesis in fibroblast cultures by the tripeptide copper complex GHK-Cu,” FEBS Letters, 1988.
  • Hsieh M-J et al., “Modulatory effects of BPC-157 on vasomotor tone and activation of the Src–Caveolin-1–eNOS pathway,” Scientific Reports, 2020.
  • He L et al., “Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs,” Frontiers in Pharmacology, 2022.
  • Józwiak M et al., “Multifunctionality and possible medical application of the BPC-157 peptide: literature and patent review,” Pharmaceuticals, 2025.
  • Xing Y et al., “Progress on the function and application of thymosin β4,” Frontiers in Endocrinology, 2021.
  • Pawar K., “Recent advances in KPV peptide delivery,” Journal of Pharmaceutics & Drug Delivery Research, 2022.
  • Lee E, Walker C, and Ayadi B., “Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study,” Alternative Therapies in Health and Medicine, 2024.
  • Sikirić P et al., “Influence of BPC-157 on nitric-oxide-related effects on gastric mucosa integrity and blood pressure,” European Journal of Pharmacology, 1997.
  • Iyer S. S. and Cheng G., “Role of interleukin-10 transcriptional regulation in inflammation and autoimmune disease,” Critical Reviews in Immunology, 2012.
  • Sosne G et al., “Thymosin β4 and the eye,” Annals of the New York Academy of Sciences, 2007.
  • Huang T et al., “Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro,” Drug Design, Development and Therapy, 2015.
  • Hara T et al., “Regenerative medicine of skeletal muscle,” Rinsho Shinkeigaku, 2005.
  • Zhang Q et al., “GHK-Cu attenuates cigarette smoke-induced pulmonary emphysema and inflammation,” Frontiers in Molecular Biosciences, 2022.
  • Park J-R et al., “The tripeptide GHK-Cu complex ameliorates LPS-induced acute lung injury in mice,” Oncotarget, 2016.
  • Kukowska M et al., “Antimicrobial activity of Gly-His-Lys conjugates as candidates for skin and tissue infections,” Bioorganic & Medicinal Chemistry Letters, 2015.
  • Cutuli M et al., “Antimicrobial effects of α-MSH peptides,” Journal of Leukocyte Biology, 2000.
  • Sikirić P et al., “Stable gastric pentadecapeptide BPC-157 as cytoprotective therapy in cardiovascular disturbances,” Biomedicines, 2022.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.